NCT02669771已完成不适用
Xtandi® Capsules 40 mg Protocol for Long-Term Specified Drug Use-Results Survey
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,018
- 主要终点
- Incidences of Adverse Events
研究概览
简要总结
The purpose of this study is to confirm the long term safety and efficacy of enzalutamide in patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •no history of treatment with enzalutamide
排除标准
- 未提供
研究组 & 干预措施
Enzalutamide group
oral
干预措施: enzalutamide (Drug)
结局指标
主要结局
Incidences of Adverse Events
时间窗: Up to 2 years
次要结局
- Change from baseline in PSA value(Up to 2 years)
- Overall Survival(Up to 2 years)
研究者
相似试验
已完成
不适用
A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPCCastration Resistant Prostate Cancer (CRPC)NCT02669147Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan160
招募中
不适用
A study to Determine Enzalutamide Long-term safety and efficacy after anti-androgen therapy for CRPC.Castration resistant prostate cancer (CRPC)JPRN-UMIN000019855Osaka University Graduate School Of Medicine200
已完成
不适用
Long Term Use Of Xalacom In Patients Glaucoma Or Ocular HypertensionGlaucomaOcular HypertensionNCT01191008Pfizer's Upjohn has merged with Mylan to form Viatris Inc.661
已完成
2 期
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast CancerAdvanced, Androgen Receptor Positive Triple Negative Breast CancerNCT01889238Pfizer118
已完成
不适用
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)Metastatic Castration Resistant Prostate CancerNCT02495974Astellas Pharma Europe Ltd.1,763